Combining immunotherapy and radiation for prostate cancer

Clinical Genitourinary Cancer

Volumn 13, Issue 1, 2015, Pages 1-9

  Finkelstein, Steven E ^a   Salenius, Sharon ^a   Mantz, Constantine A ^a   Shore, Neal D ^a   Fernandez, Eduardo B ^a   Shulman, Jesse ^a   Myslicki, Francisco A ^a   Agassi, Andre M ^a   Rotterman, Yosef ^a   Devries, Todd ^b   Sims, Robert ^b  

^a 21ST CENTURY ONCOLOGY   (United States)

^b Dendreon   (United States)

Author keywords

Cancer vaccine; Prostatic neoplasm; Radiation effects; Radiotherapy

Indexed keywords

DEATH RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; IPILIMUMAB; PLACEBO; SIPULEUCEL T; TUMOR NECROSIS FACTOR ALPHA; MONOCLONAL ANTIBODY; TISSUE EXTRACT;

CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; LEUKOCYTE COUNT; LYMPHOCYTE ACTIVATION; LYMPHOCYTOPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ADVERSE EFFECTS; CLINICAL TRIAL (TOPIC); IMMUNOTHERAPY; MALE; MULTIMODALITY CANCER THERAPY; PROSTATIC NEOPLASMS; RADIOTHERAPY;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY; TISSUE EXTRACTS;

EID: 84920422676     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2014.09.001     Document Type: Review

References (66)

1. S.E. Finkelstein, and M. Fishman Clinical opportunities in combining immunotherapy with radiation therapy Front Oncol 2 2012 169
2. M. Vanneman, and G. Dranoff Combining immunotherapy and targeted therapies in cancer treatment Nat Rev Cancer 12 2012 237 251
3. P. Lissoni, S. Meregalli, and E. Bonetto Radiotherapy-induced lymphocytopenia: changes in total lymphocyte count and in lymphocyte subpopulations under pelvic irradiation in gynecologic neoplasms J Biol Regul Homeost Agents 19 2005 153 158
4. R.M. Johnke, J.M. Edwards, and C.J. Kovacs Response of T lymphocyte populations in prostate cancer patients undergoing radiotherapy: influence of neoajuvant total androgen suppression Anticancer Res 25 2005 3159 3166
5. S.V. Harden, D.S. Routsis, and A.R. Geater Total body irradiation using a modified standing technique: a single institution 7 year experience Br J Radiol 74 2001 1041 1047
6. E.J. Hall, and A.J. Giaccia Radiobiology for the Radiologist 2012 Lippincott Williams and Wilkins Philadelphia, PA
7. L.J. Standish, C. Torkelson, and F.A. Hamill Immune defects in breast cancer patients after radiotherapy J Soc Integr Oncol 6 2008 110 121
8. S.C. Formenti, and S. Demaria Systemic effects of local radiotherapy Lancet Oncol 10 2009 718 726
9. S.E. Finkelstein, R. Timmerman, and W.H. McBride The confluence of stereotactic ablative radiotherapy and tumor immunology Clin Dev Immunol 2011 2011 439752
10. S.C. Formenti, and S. Demaria Combining radiotherapy and cancer immunotherapy: a paradigm shift J Natl Cancer Inst 105 2013 256 265
11. B. Burnette, Y.X. Fu, and R.R. Weichselbaum The confluence of radiotherapy and immunotherapy Front Oncol 2 2012 143
12. M. Chakraborty, S.I. Abrams, C.N. Coleman, K. Camphausen, J. Schlom, and J.W. Hodge External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing Cancer Res 64 2004 4328 4337
13. S.E. Finkelstein, S. Salenius, and C.A. Mantz White blood cell counts remain stable following standard radiation approaches for high-risk adenocarcinoma of the prostate Int J Rad Oncol 84 2012 S356 S357
14. N.J. Nesslinger, R.A. Sahota, and B. Stone Standard treatments induce antigen-specific immune responses in prostate cancer Clin Cancer Res 13 2007 1493 1502
15. D. Schaue, B. Comin-Anduix, and A. Ribas T-cell responses to survivin in cancer patients undergoing radiation therapy Clin Cancer Res 14 2008 4883 4890
16. C.A. Janeway Jr., P. Travers, and M. Walport Immunobiology. The Immune System in Health and Disease 4th edition 2001 Garland Science New York, NY
17. C.T. Garnett, C. Palena, and M. Chakraborty Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes Cancer Res 64 2004 7985 7994
18. E.A. Reits, J.W. Hodge, and C.A. Herberts Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy J Exp Med 203 2006 1259 1271
19. M. Chakraborty, S.I. Abrams, and K. Camphausen Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy J Immunol 170 2003 6338 6347
20. V. Ifeadi, and C. Garnett-Benson Sub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways PLoS One 7 2012 e31762
21. D.E. Hallahan, D.R. Spriggs, and M.A. Beckett Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation Proc Natl Acad Sci USA 86 1989 10104 10107
22. J.H. Hong, C.S. Chiang, and C.Y. Tsao Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation Int J Radiat Biol 75 1999 1421 1427
23. H. Ishihara, K. Tsuneoka, and A.B. Dimchev Induction of the expression of the interleukin-1 beta gene in mouse spleen by ionizing radiation Radiat Res 133 1993 321 326
24. M.D. Hurwitz, P. Kaur, and G.M. Nagaraja Radiation therapy induces circulating serum Hsp72 in patients with prostate cancer Radiother Oncol 95 2010 350 358
25. S. Quarmby, R.D. Hunter, and S. Kumar Irradiation induced expression of CD31, ICAM-1 and VCAM-1 in human microvascular endothelial cells Anticancer Res 20 2000 3375 3381
26. R. Vereecque, G. Buffenoir, and R. Gonzalez Gamma-ray irradiation induces B7.1 expression in myeloid leukaemic cells Br J Haematol 108 2000 825 831
27. Z. Chen, T. Moyana, and A. Saxena Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells Int J Cancer 93 2001 539 548
28. Y. Kotera, K. Shimizu, and J.J. Mulé Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization Cancer Res 61 2001 8105 8109
29. Y.P. Liao, C.C. Wang, and D. Schaue Local irradiation of murine melanoma affects the development of tumour-specific immunity Immunology 128 2009 e797 e804
30. Y.P. Liao, C.C. Wang, and L.H. Butterfield Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells J Immunol 173 2004 2462 2469
31. L. Galluzzi, M.C. Maiuri, and I. Vitale Cell death modalities: classification and pathophysiological implications Cell Death Differ 14 2007 1237 1243
32. L. Apetoh, F. Ghiringhelli, and A. Tesniere Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy Nat Med 13 2007 1050 1059
33. J. Fucikova, P. Kralikova, and A. Fialova Human tumor cells killed by anthracyclines induce a tumor-specific immune response Cancer Res 71 2011 4821 4833
34. R. Ganss, E. Ryschich, and E. Klar Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication Cancer Res 62 2002 1462 1470
35. C.G. Drake Combination immunotherapy approaches Ann Oncol 23 suppl 8 2012 viii41 viii46
36. S. Demaria, B. Ng, and M.L. Devitt Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated Int J Radiat Oncol Biol Phys 58 2004 862 870
37. S.M. Hiniker, D.S. Chen, and S. Reddy A systemic complete response of metastatic melanoma to local radiation and immunotherapy Transl Oncol 5 2012 404 407
38. M.A. Postow, M.K. Callahan, and C.A. Barker Immunologic correlates of the abscopal effect in a patient with melanoma N Engl J Med 366 2012 925 931
39. M.Z. Dewan, A.E. Galloway, and N. Kawashima Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody Clin Cancer Res 15 2009 5379 5388
40. D. Schaue, J.A. Ratikan, and K.S. Iwamoto Maximizing tumor immunity with fractionated radiation Int J Radiat Oncol Biol Phys 83 2012 1306 1310
41. G.O. Ahn, and J.M. Brown Influence of bone marrow-derived hematopoietic cells on the tumor response to radiotherapy: experimental models and clinical perspectives Cell Cycle 8 2009 970 976
42. E.L. Kachikwu, K.S. Iwamoto, and Y.P. Liao Radiation enhances regulatory T cell representation Int J Radiat Oncol Biol Phys 81 2011 1128 1135
43. S. Demaria, N. Bhardwaj, and W.H. McBride Combining radiotherapy and immunotherapy: a revived partnership Int J Radiat Oncol Biol Phys 63 2005 655 666
44. M. Kamrava, M.B. Bernstein, and K. Camphausen Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination? Mol Biosyst 5 2009 1262 1270
45. A.R. Kwilas, R.N. Donahue, M.B. Bernstein, and J.W. Hodge In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer Front Oncol 2 2012 104
46. A. Sharma, B. Bode, and G. Studer Radiotherapy of human sarcoma promotes an intratumoral immune effector signature Clin Cancer Res 19 2013 4843 4853
47. S.E. Finkelstein, D.M. Heimann, and C.A. Klebanoff Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer J Leukoc Biol 76 2004 333 337
48. + T cells J Exp Med 198 2003 569 580
49. S.E. Finkelstein, and M. Fishman Current status of sipuleucel-T for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer Int J Clin Rev 12 2011 10
50. United States Food and Drug Administration. Highlights of prescribing information. Provenge (sipuleucel-T). Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM210031.pdf. Accessed October 8, 2013.
51. EMA. Provenge (sipuleucel-T) Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002513/WC500151099.pdf. Accessed October 22, 2013.
52. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
53. N.A. Sheikh, D. Petrylak, and P.W. Kantoff Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer Cancer Immunol Immunother 62 2013 137 147
54. K.A. Ahmed, B.M. Barney, B.J. Davis, S.S. Park, E.D. Kwon, and K.R. Olivier Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer Front Oncol 2 2012 215
55. M.T. Milano, A.W. Katz, and H. Zhang Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study Int J Radiat Oncol Biol Phys 83 2012 878 886
56. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guideline): prostate cancer. Version 2 2014. Available at: http://www.nccn.org/professionals/physician-gls/pdf/prostate.pdf. Accessed August 1, 2014.
57. W.R. Gerritsen The evolving role of immunotherapy in prostate cancer Ann Oncol 23 suppl 8 2012 viii22 viii27
58. S.E. Finkelstein, F. Rodriguez, and M. Dunn Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy Immunotherapy 4 2012 373 382
59. S.F. Slovin, C.S. Higano, and O. Hamid Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study Ann Oncol 24 2013 1813 1821
60. E.D. Kwon, C.G. Drake, and H.I. Scher Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial Lancet Oncol 15 2014 700 712
61. S.E. Finkelstein, C. Iclozan, and M. Bui Combination of external beam radiation (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients Int J Radiat Oncol Biol Phys 82 2012 924 932
62. S.E. Finkelstein, M. Fishman, and A.O. Conley Cellular immunotherapy for soft tissue sarcoma Immunotherapy 4 2012 283 290
63. A.V. Maker, G.Q. Phan, and P. Attia Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study Ann Surg Oncol 12 2005 1005 1016
64. L. Fong, S.S. Kwek, and S. O'Brien Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF Cancer Res 69 2009 609 615
65. E.J. Small, N.S. Tchekmedyian, and B.I. Rini A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer Clin Cancer Res 13 2007 1810 1815
66. S.E. Finkelstein, A. Trotti, and N. Rao The Florida Melanoma Trial I: a prospective multi-center phase I/II trial of post operative hypofractionated adjuvant radiotherapy with concurrent interferon-alpha-2b immunotherapy in the treatment of advanced stage III melanoma with long term toxicity follow up ISRN Immunol 2012 2012 324235